Two more biotechnology products gain orphan drug status - Products for organ transplantation, lung cancer

被引：0
|
作者：
不详
机构：
来源：
BIOTECHNOLOGY LAW REPORT | 1998年 / 17卷 / 06期
关键词：
BioTransplant; Immunomedics; lung cancer; orphan drugs; transplantation;
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：771 / 772
页数：2
相关论文
共 9 条
  • [1] Two more biotechnology products receive orphan drug designation
    不详
    [J]. BIOTECHNOLOGY LAW REPORT, 1999, 18 (05) : 407 - 408
  • [2] Two more biotechnology products receive orphan drug designation
    不详
    [J]. BIOTECHNOLOGY LAW REPORT, 2000, 19 (04) : 417 - 417
  • [3] Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
    Mulder, Jorn
    van Rossum, Tobias
    Mariz, Segundo
    Magrelli, Armando
    de Boer, Anthonius
    Pasmooij, Anna M. G.
    Stoyanova-Beninska, Violeta
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] DOES ORPHAN DRUG STATUS CONFER ANY BENEFITS FOR PRODUCTS UNDERGOING HTA APPRAISAL BY NICE IN ENGLAND?
    Foxon, G.
    Craddy, P.
    Wilson, C.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S180 - S180
  • [5] Healing beauty? More biotechnology cosmetic products that claim drug-like properties reach the market
    Rinaldi, Andrea
    [J]. EMBO REPORTS, 2008, 9 (11) : 1073 - 1077
  • [6] China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
    Zhou, Ming
    Chen, Xiaoyuan
    Zhang, Hong
    Xia, Lin
    Tong, Xin
    Zou, Limin
    Hao, Ruimin
    Pan, Jianhong
    Zhao, Xiao
    Chen, Dongmei
    Song, Yuanyuan
    Qi, Yueli
    Tang, Ling
    Liu, Zhifang
    Gao, Rong
    Shi, Yuankai
    Yang, Zhimin
    [J]. CANCER COMMUNICATIONS, 2019, 39
  • [7] Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2.3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer
    Bridges, Benjamin B.
    Thomas, Leno
    Hausner, Petr F.
    Doyle, L. Austin
    Bedor, Michelle
    Smith, Ruth
    Brahmer, Julie
    Edelman, Martin J.
    [J]. LUNG CANCER, 2008, 61 (01) : 61 - 66
  • [8] Phase II trial of gemcitabine/carboplatin (GC) followed by paclitaxel (P) in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer (NSCLC)
    Bridges, B. B.
    Thomas, L.
    Hausner, P.
    Doyle, L. A.
    Bedor, M.
    Smith, R.
    Brahmer, J.
    Edelman, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Current status of gemcitabine (Gemzar) and MTA in the treatment of non-small cell lung cancer - Off-label uses of commercial products or investigational uses not cleared for marketing that are referenced by the authors in this journal supplement and that relate to Eli Lilly and Company, its subsidiaries or business partners
    不详
    [J]. SEMINARS IN ONCOLOGY, 1999, 26 (01) : 38 - 38
1